Research Peptides

SR9009 (Stenabolic)

SR9009 (Stenabolic) is a synthetic agonist of the nuclear receptor Rev-Erbα, a key component of the circadian clock machinery that links circadian rhythms to metabolic regulation. Developed at The Scripps Research Institute, SR9009 activates Rev-Erbα to modulate the expression of genes involved in lipid and glucose metabolism, mitochondrial biogenesis, and inflammatory responses. In animal studies, SR9009 increased exercise capacity, reduced fat mass, decreased plasma cholesterol and triglycerides, and altered circadian behavior patterns. Despite promising preclinical data, SR9009 has very low oral bioavailability, and no human clinical trials have been conducted.

Technical Specifications

Sequence / StructureNon-peptide small molecule Rev-Erbα agonist
Molecular Weight437.94 g/mol
Purity≥99%
AppearanceWhite to off-white powder
StorageStore at room temperature, protect from light
SolubilitySoluble in DMSO and ethanol

Application Areas

  • Circadian rhythm research
  • Rev-Erbα pharmacology
  • Metabolic regulation studies
  • Lipid metabolism research
  • Exercise physiology research

Published Research on SR9009 (Stenabolic)

Solt LA, Wang Y, Banerjee S, et al. (2012) — Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature. DOI: 10.1038/nature11030

Woldt E, Sebti Y, Solt LA, et al. (2013) — Rev-erb-α modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nat Med. DOI: 10.1038/nm.3213

Frequently Asked Questions About SR9009 (Stenabolic)

SR9009 (Stenabolic) is a synthetic Rev-Erbα agonist that modulates circadian clock-controlled metabolic pathways, enhancing exercise capacity and fat metabolism in preclinical models.

Our wholesale SR9009 is ≥99% purity with HPLC verification.

SR9009 is used in circadian biology, Rev-Erbα signaling, metabolic regulation, and exercise physiology research.

Store at room temperature protected from light and moisture.

Contact our team for MOQ and bulk pricing.

SR9009 is neither — it is a Rev-Erbα agonist (small molecule). It is often misclassified as a SARM but has a completely different mechanism targeting circadian nuclear receptors.

Related Research Peptides

Request Price List